
Opinion|Videos|May 28, 2025
Navigating the Heterogeneous Progression of Duchenne Muscular Dystrophy
Author(s)Diana Castro, MD
Duchenne Muscular Dystrophy progresses with motor delays, varying deterioration rates, and impacts multiple organs, highlighting the need for early intervention.
Advertisement
Episodes in this series

Summary for Physicians
Disease Progression in Duchenne Muscular Dystrophy (DMD)DMD
DMD progresses in stages, with initial motor milestone delays and a gradual loss of motor function. Key points include the following:
- Early delays in motor milestones like such as standing, walking, running, and climbing stairs.
- Maximum motor capacity typically achieved by age 6.5½, followed by a noticeable decline in function. Some children may lose the ability to walk as early as age 7 to -8 years, while others may progress more slowly.
- Wide range of progression: Some mutations (e.g.eg, those amenable to Eexon 44 skipping) may result in slower progression and less severe weakness.
- Dystrophin deficiency leads to muscle cell damage and affects multiple organs, including the heart, lungs, and digestive system, contributing to the disease's progressive nature.
- Respiratory and cardiac involvement develop with age, and early death was common before the use of steroids and other therapies.
- Prognosis improvement: With steroids and new therapies, life expectancy has increased, and newborn screening may further improve outcomes by enabling earlier interventions.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Cladribine Tablets Show Ability to Improve or Stabilize Cognitive Function in Patients With Relapsing Multiple Sclerosis
2
Cladribine Maintains Efficacy, Safety Profile in Older Patients With Multiple Sclerosis
3
Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers
4
CD40L Inhibitor Frexalimab Enters Phase 3 FREXITE Trial of Non-Relapsing Secondary Progressive Multiple Sclerosis
5











